|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TSC22D3 |
Gene summary for TSC22D3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TSC22D3 | Gene ID | 1831 |
| Gene name | TSC22 domain family member 3 | |
| Gene Alias | DIP | |
| Cytomap | Xq22.3 | |
| Gene Type | protein-coding | GO ID | GO:0001776 | UniProtAcc | Q5JRJ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1831 | TSC22D3 | GSM4909286 | Human | Breast | IDC | 2.89e-02 | -2.08e-01 | 0.1081 |
| 1831 | TSC22D3 | GSM4909290 | Human | Breast | IDC | 3.01e-02 | 3.01e-01 | 0.2096 |
| 1831 | TSC22D3 | GSM4909293 | Human | Breast | IDC | 2.12e-19 | 4.16e-01 | 0.1581 |
| 1831 | TSC22D3 | GSM4909297 | Human | Breast | IDC | 4.63e-08 | 3.26e-01 | 0.1517 |
| 1831 | TSC22D3 | GSM4909298 | Human | Breast | IDC | 1.26e-05 | 2.39e-01 | 0.1551 |
| 1831 | TSC22D3 | GSM4909304 | Human | Breast | IDC | 1.56e-05 | 2.84e-01 | 0.1636 |
| 1831 | TSC22D3 | GSM4909306 | Human | Breast | IDC | 1.53e-28 | 6.60e-01 | 0.1564 |
| 1831 | TSC22D3 | GSM4909308 | Human | Breast | IDC | 9.68e-14 | 4.55e-01 | 0.158 |
| 1831 | TSC22D3 | GSM4909311 | Human | Breast | IDC | 1.39e-05 | -5.53e-02 | 0.1534 |
| 1831 | TSC22D3 | GSM4909312 | Human | Breast | IDC | 8.60e-05 | 3.43e-01 | 0.1552 |
| 1831 | TSC22D3 | GSM4909313 | Human | Breast | IDC | 2.99e-02 | 3.64e-01 | 0.0391 |
| 1831 | TSC22D3 | GSM4909317 | Human | Breast | IDC | 1.23e-17 | 6.35e-01 | 0.1355 |
| 1831 | TSC22D3 | GSM4909319 | Human | Breast | IDC | 2.08e-24 | 4.19e-01 | 0.1563 |
| 1831 | TSC22D3 | GSM4909320 | Human | Breast | IDC | 2.77e-02 | -1.96e-01 | 0.1575 |
| 1831 | TSC22D3 | GSM4909321 | Human | Breast | IDC | 2.85e-07 | 3.55e-01 | 0.1559 |
| 1831 | TSC22D3 | M1 | Human | Breast | IDC | 5.02e-03 | 3.18e-01 | 0.1577 |
| 1831 | TSC22D3 | DCIS2 | Human | Breast | DCIS | 3.13e-31 | 3.59e-01 | 0.0085 |
| 1831 | TSC22D3 | LZE4T | Human | Esophagus | ESCC | 1.31e-03 | 3.66e-01 | 0.0811 |
| 1831 | TSC22D3 | LZE7T | Human | Esophagus | ESCC | 1.14e-07 | 1.69e+00 | 0.0667 |
| 1831 | TSC22D3 | LZE8T | Human | Esophagus | ESCC | 4.57e-02 | 5.77e-01 | 0.067 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000268311 | Breast | IDC | negative regulation of immune system process | 55/1434 | 434/18723 | 1.53e-04 | 2.67e-03 | 55 |
| GO:004887214 | Breast | IDC | homeostasis of number of cells | 36/1434 | 272/18723 | 9.10e-04 | 1.04e-02 | 36 |
| GO:0070229 | Breast | IDC | negative regulation of lymphocyte apoptotic process | 7/1434 | 30/18723 | 6.48e-03 | 4.56e-02 | 7 |
| GO:000268321 | Breast | DCIS | negative regulation of immune system process | 57/1390 | 434/18723 | 1.81e-05 | 4.35e-04 | 57 |
| GO:004887224 | Breast | DCIS | homeostasis of number of cells | 36/1390 | 272/18723 | 5.17e-04 | 6.73e-03 | 36 |
| GO:004887227 | Esophagus | HGIN | homeostasis of number of cells | 54/2587 | 272/18723 | 3.50e-03 | 3.23e-02 | 54 |
| GO:0048872111 | Esophagus | ESCC | homeostasis of number of cells | 163/8552 | 272/18723 | 1.40e-06 | 1.69e-05 | 163 |
| GO:00069707 | Esophagus | ESCC | response to osmotic stress | 57/8552 | 84/18723 | 3.26e-05 | 2.70e-04 | 57 |
| GO:00718871 | Esophagus | ESCC | leukocyte apoptotic process | 65/8552 | 106/18723 | 8.39e-04 | 4.32e-03 | 65 |
| GO:000268316 | Esophagus | ESCC | negative regulation of immune system process | 231/8552 | 434/18723 | 8.48e-04 | 4.36e-03 | 231 |
| GO:00702271 | Esophagus | ESCC | lymphocyte apoptotic process | 46/8552 | 72/18723 | 1.39e-03 | 6.62e-03 | 46 |
| GO:0070231 | Esophagus | ESCC | T cell apoptotic process | 31/8552 | 50/18723 | 1.48e-02 | 4.79e-02 | 31 |
| GO:000697011 | Liver | Cirrhotic | response to osmotic stress | 34/4634 | 84/18723 | 1.06e-03 | 7.40e-03 | 34 |
| GO:004887212 | Liver | Cirrhotic | homeostasis of number of cells | 89/4634 | 272/18723 | 1.76e-03 | 1.12e-02 | 89 |
| GO:004887222 | Liver | HCC | homeostasis of number of cells | 147/7958 | 272/18723 | 7.48e-05 | 6.70e-04 | 147 |
| GO:00069702 | Liver | HCC | response to osmotic stress | 52/7958 | 84/18723 | 2.58e-04 | 1.92e-03 | 52 |
| GO:004887220 | Oral cavity | OSCC | homeostasis of number of cells | 152/7305 | 272/18723 | 1.08e-08 | 2.23e-07 | 152 |
| GO:00069706 | Oral cavity | OSCC | response to osmotic stress | 50/7305 | 84/18723 | 1.11e-04 | 8.15e-04 | 50 |
| GO:0071887 | Oral cavity | OSCC | leukocyte apoptotic process | 60/7305 | 106/18723 | 1.78e-04 | 1.21e-03 | 60 |
| GO:000268310 | Oral cavity | OSCC | negative regulation of immune system process | 204/7305 | 434/18723 | 3.72e-04 | 2.27e-03 | 204 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TSC22D3 | SNV | Missense_Mutation | novel | c.145C>T | p.Arg49Trp | p.R49W | Q99576 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.895) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TSC22D3 | SNV | Missense_Mutation | c.274C>T | p.Arg92Cys | p.R92C | Q99576 | protein_coding | deleterious(0.01) | benign(0.134) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| TSC22D3 | SNV | Missense_Mutation | c.98N>C | p.Ser33Thr | p.S33T | Q99576 | protein_coding | tolerated_low_confidence(0.27) | benign(0.005) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR | |
| TSC22D3 | SNV | Missense_Mutation | novel | c.337N>A | p.Val113Met | p.V113M | Q99576 | protein_coding | deleterious(0.04) | possibly_damaging(0.698) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TSC22D3 | SNV | Missense_Mutation | c.37N>A | p.Gly13Ser | p.G13S | Q99576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-IR-A3L7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TSC22D3 | SNV | Missense_Mutation | c.361N>A | p.Glu121Lys | p.E121K | Q99576 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TSC22D3 | SNV | Missense_Mutation | c.209N>A | p.Arg70Gln | p.R70Q | Q99576 | protein_coding | tolerated(0.12) | probably_damaging(0.979) | TCGA-EI-6510-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TSC22D3 | SNV | Missense_Mutation | novel | c.226C>T | p.Pro76Ser | p.P76S | Q99576 | protein_coding | tolerated(0.33) | benign(0.005) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TSC22D3 | SNV | Missense_Mutation | c.361N>A | p.Glu121Lys | p.E121K | Q99576 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TSC22D3 | SNV | Missense_Mutation | novel | c.80N>A | p.Ser27Asn | p.S27N | Q99576 | protein_coding | deleterious_low_confidence(0.05) | benign(0.043) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1831 | TSC22D3 | NA | HYDROCORTISONE | HYDROCORTISONE | 15728202 | |
| 1831 | TSC22D3 | NA | CORTICOSTEROIDS | 17208592 | ||
| 1831 | TSC22D3 | NA | DEXAMETHASONE | DEXAMETHASONE | 15728202,12707381 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |